By Professor Richard Bryan Lock

Journal articles

Gorlick R; Kolb EA; Keir ST; Maris JM; Lock RB; Carol H; Reynolds CP; Kang MH; Billups CA; Collins J; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA, 2016, 'Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 63, pp. 443 - 450, http://dx.doi.org/10.1002/pbc.25826

Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW, 2016, 'The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid Leukemia', Cancer Research, 76, pp. 1158 - 1169, http://dx.doi.org/10.1158/0008-5472.CAN-15-1070

Lalaoui N; Hänggi K; Brumatti G; Chau D; Nguyen NYN; Vasilikos L; Spilgies LM; Heckmann DA; Ma C; Ghisi M; Salmon JM; Matthews GM; de Valle E; Moujalled DM; Menon MB; Spall SK; Glaser SP; Richmond J; Lock RB; Condon SM; Gugasyan R; Gaestel M; Guthridge M; Johnstone RW; Munoz L; Wei A; Ekert PG; Vaux DL; Wong WWL; Silke J, 2016, 'Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics', Cancer Cell, 29, pp. 145 - 158, http://dx.doi.org/10.1016/j.ccell.2016.01.006

Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2016, 'Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program', Pediatric Blood and Cancer, 63, pp. 276 - 286, http://dx.doi.org/10.1002/pbc.25727

El-Hoss J; Jing D; Evans K; Toscan C; Xie J; Lee H; Taylor RA; Lawrence MG; Risbridger GP; MacKenzie KL; Sutton R; Lock RB, 2016, 'A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts', Oncotarget, 7, pp. 60475 - 60490, http://dx.doi.org/10.18632/oncotarget.11125

Smith AM; Dun MD; Lee EM; Harrison C; Kahl R; Flanagan H; Panicker N; Mashkani B; Don AS; Morris J; Toop H; Lock RB; Powell JA; Thomas D; Guthridge MA; Moore A; Ashman LK; Skelding KA; Enjeti A; Verrills NM, 2016, 'Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors', Oncotarget, 7, pp. 47465 - 47478, http://dx.doi.org/10.18632/oncotarget.10167

Yadav BD; Samuels AL; Wells JE; Sutton R; Venn NC; Bendak K; Anderson D; Marshall GM; Cole CH; Beesley AH; Kees UR; Lock RB, 2016, 'Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia', Oncotarget, 7, pp. 58728 - 58742, http://dx.doi.org/10.18632/oncotarget.11233

Kang MH; Reynolds CP; Kolb EA; Gorlick R; Carol H; Lock R; Keir ST; Maris JM; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2016, 'Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, http://dx.doi.org/10.1002/pbc.26064

Manesh DM; El-Hoss J; Evans K; Richmond J; Toscan CE; Bracken LS; Hedrick A; Sutton R; Marshall GM; Wilson WR; Kurmasheva RT; Billups C; Houghton PJ; Smith MA; Carol H; Lock RB, 2015, 'AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia', Blood, 126, pp. 1193 - 1202, http://dx.doi.org/10.1182/blood-2014-12-618900

Lee EM; Yee D; Busfield SJ; McManus JF; Cummings N; Vairo G; We A; Ramshaw HS; Powell JA; Lopez AF; Lewis ID; McCall MN; Lock RB, 2015, 'Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice', Haematologica, 100, pp. 914 - 926, http://dx.doi.org/10.3324/haematol.2014.113092

Toscan CE; Rahimi M; Bhadbhade M; Pickford R; McAlpine SR; Lock RB, 2015, 'Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts', Organic and Biomolecular Chemistry, 13, pp. 6299 - 6312, http://dx.doi.org/10.1039/c5ob00779h

Kolb EA; Gorlick R; Keir ST; Maris JM; Kang MH; Reynolds CP; Lock RB; Carol H; Wu J; Kurmasheva RT; Houghton PJ; Smith MA, 2015, 'Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 62, pp. 1106 - 1109, http://dx.doi.org/10.1002/pbc.25329

Tursky ML; Beck D; Thoms JAI; Huang Y; Kumari A; Unnikrishnan A; Knezevic K; Evans K; Richards LA; Lee E; Morris J; Goldberg L; Izraeli S; Wong JWH; Olivier J; Lock RB; MacKenzie KL; Pimanda JE, 2015, 'Overexpression of ERG in cord blood progenitors promotes expansion and recapitulates molecular signatures of high ERG leukemias', Leukemia, 29, pp. 819 - 827, http://dx.doi.org/10.1038/leu.2014.299

Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB, 2015, 'Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia', Clinical Cancer Research, 21, pp. 1395 - 1405, http://dx.doi.org/10.1158/1078-0432.CCR-14-2300

Smith MA; Reynolds CP; Kang MH; Kolb EA; Gorlick R; Carol H; Lock RB; Keir ST; Maris JM; Billups CA; Lyalin D; Kurmasheva RT; Houghton PJ, 2015, 'Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric Cancer Models in the Pediatric Preclinical Testing Program', Clinical Cancer Research, 21, pp. 819 - 832, http://dx.doi.org/10.1158/1078-0432.CCR-14-2572

Dolai S; Lock R, 2015, 'Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia', Blood, 125, pp. 1759 - 1767, http://dx.doi.org/10.1182/blood-2014-06-580480

Suryani S; Bracken LS; Harvey RC; Sia KCS; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB, 2015, 'Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia', Molecular Cancer Therapeutics, 14, pp. 364 - 374, http://dx.doi.org/10.1158/1535-7163.MCT-14-0647

Jing D; Bhadri VA; Beck D; Thoms JAI; Yakob NA; Wong JWH; Knezevic K; Pimanda JE; Lock RB, 2015, 'Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.', Blood, 125, pp. 273 - 283, http://dx.doi.org/10.1182/blood-2014-05-576470

Goossens S; Radaelli E; Blanchet O; Durinck K; Van Der Meulen J; Peirs S; Taghon T; Tremblay CS; Costa M; Ghahremani MF; De Medts J; Bartunkova S; Haigh K; Schwab C; Farla N; Pieters T; Matthijssens F; Van Roy N; Best JA; Deswarte K; Bogaert P; Carmichael C; Rickard A; Suryani S; Bracken LS; Alserihi R; Canté-Barrett K; Haenebalcke L; Clappier E; Rondou P; Slowicka K; Huylebroeck D; Goldrath AW; Janzen V; McCormack MP; Lock RB; Curtis DJ; Harrison C; Berx G; Speleman F; Meijerink JPP; Soulier J; Van Vlierberghe P; Haigh JJ, 2015, 'ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling', Nature Communications, 6, pp. 5794, http://dx.doi.org/10.1038/ncomms6794

Carol H; Fan MMY; Harasym TO; Boehm I; Mayer LD; Houghton P; Smith MA; Lock RB, 2015, 'Efficacy of CPX-351, (cytarabine: DAunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 62, pp. 65 - 71, http://dx.doi.org/10.1002/pbc.25133

Smith MA; Hampton OA; Reynolds CP; Kang MH; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Kurmasheva RT; Wheeler DA; Houghton PJ, 2015, 'Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673', Pediatric Blood and Cancer, 62, pp. 91 - 98, http://dx.doi.org/10.1002/pbc.25201

Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2015, 'Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program', Pediatric Blood and Cancer, 63, pp. 276 - 286, http://dx.doi.org/10.1002/pbc.25727

Nowak D; Liem NLM; Mossner M; Klaumünzer M; Papa RA; Nowak V; Jann JC; Akagi T; Kawamata N; Okamoto R; Thoennissen NH; Kato M; Sanada M; Hofmann WK; Ogawa S; Marshall GM; Lock RB; Koeffler HP, 2015, 'Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance', Experimental Hematology, 43, pp. 32 - 43, http://dx.doi.org/10.1016/j.exphem.2014.09.007

Davies C; Hogarth LA; Mackenzie KL; Hall AG; Lock RB, 2015, 'p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.', Cell Cycle, 14, pp. 3602 - 3612, http://dx.doi.org/10.1080/15384101.2015.1100774

Toscan CE; Failes T; Arndt GM; Lock RB; Arndt G, 2014, 'High-throughput screening of human leukemia xenografts to identify dexamethasone sensitizers', Journal of Biomolecular Screening, 19, pp. 1391 - 1401, http://dx.doi.org/10.1177/1087057114546550

Bruedigam C; Bagger FO; Heidel FH; Paine Kuhn C; Guignes S; Song A; Austin R; Vu T; Lee E; Riyat S; Moore AS; Lock RB; Bullinger L; Hill GR; Armstrong SA; Williams DA; Lane SW, 2014, 'Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy', Cell Stem Cell, 15, pp. 775 - 790, http://dx.doi.org/10.1016/j.stem.2014.11.010

Suryani S; Carol H; Chonghaile TN; Frismantas V; Sarmah C; High L; Bornhauser B; Cowley MJ; Szymanska B; Evans K; Boehm I; Tonna E; Jones L; Manesh DM; Kurmasheva RT; Billups C; Kaplan W; Letai A; Bourquin J-P; Houghton PJ; Smith MA; Lock RB, 2014, 'Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts.', Clin Cancer Res, 20, pp. 4520 - 4531, http://dx.doi.org/10.1158/1078-0432.CCR-14-0259

Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB, 2014, 'Initial Testing (Stage 1) of the Notch Inhibitor PF-03084014, by the Pediatric Preclinical Testing Program (vol 61, pg 1493, 2014)', PEDIATRIC BLOOD & CANCER, 61, pp. 1716 - 1716, http://dx.doi.org/10.1002/pbc.25186

Samuels AL; Beesley AH; Yadav BD; Papa RA; Sutton R; Anderson D; Marshall GM; Cole CH; Kees UR; Lock RB, 2014, 'A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.', Blood Cancer J, 4, pp. e232, http://dx.doi.org/10.1038/bcj.2014.52

Kang MH; Reynolds CP; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2014, 'Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program', Pediatric Blood and Cancer, 61, pp. 1486 - 1489, http://dx.doi.org/10.1002/pbc.24989

Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Wu J; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB, 2014, 'Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 61, pp. 1493 - 1496, http://dx.doi.org/10.1002/pbc.25026

Wong NC; Bhadri VA; Maksimovic J; Parkinson-Bates M; Ng J; Craig JM; Saffery R; Lock RB, 2014, 'Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance', BMC Genomics, 15, http://dx.doi.org/10.1186/1471-2164-15-416

Jamieson SMF; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR, 2014, 'A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells', Biochemical Pharmacology, 88, pp. 36 - 45, http://dx.doi.org/10.1016/j.bcp.2013.12.019

Shahbazi J; Scarlett CJ; Norris MD; Liu B; Haber M; Tee AE; Carrier A; Biankin AV; London WB; Marshall GM; Lock RB; Liu T, 2014, 'Histone Deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1', Oncotarget, 5, pp. 4257 - 4268, http://dx.doi.org/10.18632/oncotarget.1991

Gorlick R; Kolb EA; Maris JM; Reynolds CP; Kang MH; Carol H; Lock RB; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA; Keir ST, 2014, 'Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 61, pp. 158 - 164, http://dx.doi.org/10.1002/pbc.24616

Lock RB; Busfield S; Biondo M; Wong M; Ramshaw H; Lee E; Ghosh S; Braley H; Panousis C; Roberts A; He S; Thomas D; Fabri L; Vairo G; Lock REA, 2014, 'Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC', Leukemia, advance online publication, 9 May 2014, pp. 2213 - 2221, http://dx.doi.org/10.1038/leu.2014.128

Waibel M; Solomon VS; Knight DA; Ralli RA; Kim SK; Banks KM; Vidacs E; Virely C; Sia KCS; Bracken LS; Collins-Underwood R; Drenberg C; Ramsey LB; Meyer SC; Takiguchi M; Dickins RA; Levine R; Ghysdael J; Dawson MA; Lock RB; Mullighan CG; Johnstone RW, 2013, 'Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors', Cell Reports, 5, pp. 1047 - 1059, http://dx.doi.org/10.1016/j.celrep.2013.10.038

Carol H; Gorlick R; Kolb EA; Morton CL; Moradi Manesh D; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak A; Hickson I; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA; Lock R, 2013, 'Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program', Pediatric Blood & Cancer, 61, pp. 245 - 252, http://dx.doi.org/10.1002/pbc.24724

Kolb EA; Gorlick R; Reynolds CP; Kang MH; Carol H; Lock R; Keir ST; Maris JM; Billups CA; Desjardins C; Kurmasheva RT; Houghton PJ; Smith MA, 2013, 'Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 60, pp. 1325 - 1332, http://dx.doi.org/10.1002/pbc.24517

Lock RB; Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA, 2013, 'Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 60, pp. E42 - E45, http://dx.doi.org/10.1002/pbc.24451

Reynolds CP; Kang MH; Carol H; Lock R; Gorlick R; Kolb EA; Kurmasheva RT; Keir ST; Maris JM; Billups CA; Houghton PJ; Smith MA, 2013, 'Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program', Pediatric Blood and Cancer, 60, pp. 791 - 798, http://dx.doi.org/10.1002/pbc.24301

Carol H; Reynolds CP; Kang MH; Keir ST; Maris JM; Gorlick R; Kolb EA; Billups CA; Geier B; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB, 2013, 'Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program', Pediatric Blood and Cancer, 60, pp. 633 - 641, http://dx.doi.org/10.1002/pbc.24235

Carol H; Szymanska B; Evans K; Boehm I; Houghton PJ; Smith MA; Lock RB, 2013, 'The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia', Clinical Cancer Research, 19, pp. 1795 - 1805, http://dx.doi.org/10.1158/1078-0432.CCR-12-3613

Keir ST; Maris JM; Reynolds CP; Kang MH; Kolb EA; Gorlick R; Lock R; Carol H; Morton CL; Wu J; Kurmasheva RT; Houghton PJ; Smith MA, 2013, 'Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program', Pediatric Blood and Cancer, 60, pp. 783 - 790, http://dx.doi.org/10.1002/pbc.24368

Oram SH; Thoms J; Sive J; Calero-Nieto FJ; Kinston SJ; Schuette J; Knezevic K; Lock RB; Pimanda JE; Gottgens B, 2013, 'Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia', Leukemia, 27, pp. 1348 - 1357, http://dx.doi.org/10.1038/leu.2013.2

Piazza RG; Magistroni V; Mogavero A; Andreoni F; Ambrogio C; Chiarle R; Mologni L; Bachmann PS; Lock RB; Collini P; Gambacorti-passerini C, 2013, 'Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex', Neoplasia, 15, pp. 511 - 522, http://dx.doi.org/10.1593/neo.121784

Malyukova A; Brown S; Papa R; O'Brien R; Giles J; Trahair TN; Dalla Pozza L; Sutton R; Liu T; Haber M; Norris MD; Lock RB; Sangfelt O; Marshall GM, 2013, 'FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation', Leukemia, 27, pp. 1053 - 1062, http://dx.doi.org/10.1038/leu.2012.361

Lock RB, 2013, 'Targeting acute myeloid leukemia by dual inhibition of P13K signalling and Cdk9-mediated Mcl-1 transcription', Blood, 122, pp. 738 - 748, http://dx.doi.org/10.1182/blood-2012-08-447441

Lu H; Kojima K; Battula VL; Korchin B; Shi Y; Chen Y; Andreeff M; Konopleva M; Spong S; Thomas DA; Kantarjian H; Lock RB, 2013, 'Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth', Annals of Hematology, pp. 1 - 8, http://dx.doi.org/10.1007/s00277-013-1939-2

Shahbazi J; Lock RB; Liu T, 2013, 'Tumor protein 53-induced nuclear protein 1 enhances p53 function and represses tumorigenesis', Frontiers in Genetics, 13, pp. Art. No. 80, http://dx.doi.org/10.3389/fgene.2013.00080

Back to profile page